[go: up one dir, main page]

MX373162B - Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). - Google Patents

Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).

Info

Publication number
MX373162B
MX373162B MX2017013101A MX2017013101A MX373162B MX 373162 B MX373162 B MX 373162B MX 2017013101 A MX2017013101 A MX 2017013101A MX 2017013101 A MX2017013101 A MX 2017013101A MX 373162 B MX373162 B MX 373162B
Authority
MX
Mexico
Prior art keywords
sup
nmda
modulators
pyridopyrimidinones
aspartate
Prior art date
Application number
MX2017013101A
Other languages
English (en)
Other versions
MX2017013101A (es
Inventor
Aijun Lu
Benjamin Sellers
Elisia Villemure
Guosheng Wu
Matthew Volgraf
Yu Jiang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017013101A publication Critical patent/MX2017013101A/es
Publication of MX373162B publication Critical patent/MX373162B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos piridopirimidinona de fórmula I: (ver Fórmula) o sales de los mismos farmacéuticamente aceptable, en donde X, R1, R2, R3, R4, R5 y R6 son tal como se define en la presente descripción, así como composiciones farmacéuticas que comprenden tales compuestos y métodos de tratamiento que usan tales compuestos.
MX2017013101A 2015-04-15 2016-04-12 Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). MX373162B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015076617 2015-04-15
PCT/EP2016/057962 WO2016166078A1 (en) 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as nmda receptor modulators

Publications (2)

Publication Number Publication Date
MX2017013101A MX2017013101A (es) 2018-01-30
MX373162B true MX373162B (es) 2020-04-21

Family

ID=55809078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013101A MX373162B (es) 2015-04-15 2016-04-12 Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).

Country Status (19)

Country Link
US (1) US10280165B2 (es)
EP (1) EP3283487B1 (es)
JP (2) JP6847851B2 (es)
KR (1) KR20170137137A (es)
CN (1) CN107531696B (es)
AU (1) AU2016248886B2 (es)
BR (1) BR112017021083A2 (es)
CA (1) CA2982217A1 (es)
CL (1) CL2017002498A1 (es)
CO (1) CO2017009989A2 (es)
CR (1) CR20170462A (es)
IL (1) IL254921B (es)
MX (1) MX373162B (es)
PE (1) PE20180316A1 (es)
PH (1) PH12017501876A1 (es)
RU (1) RU2717665C2 (es)
SG (1) SG11201708294YA (es)
UA (1) UA120647C2 (es)
WO (1) WO2016166078A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3055315T3 (pl) 2013-10-11 2018-12-31 F. Hoffmann-La Roche Ag Tiazolopirymidynony jako modulatory aktywności receptora nmda
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators
PL3386591T3 (pl) 2015-12-09 2021-02-22 Novartis Ag Heteroaromatyczne modulatory receptorów nmda i ich zastosowania
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
SG11202101125VA (en) 2018-08-03 2021-03-30 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
JP7741100B2 (ja) 2020-05-04 2025-09-17 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CA2528771A1 (en) * 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
AU2008213836A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
KR101811549B1 (ko) * 2013-06-19 2017-12-26 에프. 호프만-라 로슈 아게 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체
PL3055315T3 (pl) * 2013-10-11 2018-12-31 F. Hoffmann-La Roche Ag Tiazolopirymidynony jako modulatory aktywności receptora nmda
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators

Also Published As

Publication number Publication date
CN107531696A (zh) 2018-01-02
CO2017009989A2 (es) 2018-01-05
RU2017139254A3 (es) 2019-09-30
WO2016166078A1 (en) 2016-10-20
BR112017021083A2 (pt) 2018-07-03
KR20170137137A (ko) 2017-12-12
IL254921B (en) 2021-02-28
AU2016248886A1 (en) 2017-10-12
JP2018511627A (ja) 2018-04-26
CN107531696B (zh) 2021-03-16
JP2021046428A (ja) 2021-03-25
JP6847851B2 (ja) 2021-03-24
PH12017501876A1 (en) 2018-02-26
EP3283487B1 (en) 2019-10-16
IL254921A0 (en) 2017-12-31
HK1245259A1 (zh) 2018-08-24
SG11201708294YA (en) 2017-11-29
CA2982217A1 (en) 2016-10-20
EP3283487A1 (en) 2018-02-21
US10280165B2 (en) 2019-05-07
RU2717665C2 (ru) 2020-03-24
UA120647C2 (uk) 2020-01-10
MX2017013101A (es) 2018-01-30
RU2017139254A (ru) 2019-05-15
US20180127414A1 (en) 2018-05-10
PE20180316A1 (es) 2018-02-09
AU2016248886B2 (en) 2020-09-10
CR20170462A (es) 2018-02-01
CL2017002498A1 (es) 2018-04-20

Similar Documents

Publication Publication Date Title
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
MX373162B (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
MX376062B (es) Agonistas del receptor muscarinico.
MX379264B (es) Profarmacos de amidas de piridona utiles como moduladores de canales de sodio.
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
MX372781B (es) Ciclopentanos 1,2-sustituidos como antagonistas del receptor de la orexina.
MX381967B (es) Compuestos de 2,3-dihidrobenzofuran-5-ilo como inhibidores de quinasas dyrk.
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX376283B (es) Compuestos de imidazopiridazina.
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
MX382175B (es) Composiciones de profármaco de monometilfumarato
MX380424B (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
PH12015502632A1 (en) Cxcr7 receptor modulators
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов

Legal Events

Date Code Title Description
FG Grant or registration